<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605370</url>
  </required_header>
  <id_info>
    <org_study_id>11-007035</org_study_id>
    <nct_id>NCT01605370</nct_id>
  </id_info>
  <brief_title>Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?</brief_title>
  <acronym>Inapprop</acronym>
  <official_title>Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if a drug called nebivolol can reverse inappropriate&#xD;
      left ventricular mass (LVM) when compared to the standard of care drug metoprolol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In response to chronic pressure overload by arterial hypertension, the cardiac left ventricle&#xD;
      undergoes hypertrophy, that is, increases its wall thickness and, therefore, its mass, to&#xD;
      sustain the elevated workload. Such anatomical remodeling can be considered adaptive or&#xD;
      appropriate. However, in a considerable number of patients with arterial hypertension, the&#xD;
      increase in the left ventricular mass is excessive and, thus, inappropriate.&#xD;
&#xD;
      Ventricular mass is inappropriate when its amount surpasses the physical need of the&#xD;
      ventricle to sustain the elevated workload. Therefore, ventricular mass can be inappropriate&#xD;
      even in patients without arterial hypertension or without hypertrophy identified by&#xD;
      echocardiography (echo). We can mathematically predict an appropriate amount of mass and&#xD;
      observe the actual mass in individual patients based on ventricular workload and wall&#xD;
      thickness, respectively, noninvasively evaluated by echo. By comparing the observed&#xD;
      ventricular mass to the predicted one, we determine whether its amount is inappropriate. It&#xD;
      follows that by therapeutically normalizing blood pressure in hypertension and thus&#xD;
      eliminating the elevated workload, then any ventricular hypertrophy represents an&#xD;
      inappropriate mass.&#xD;
&#xD;
      Inappropriate ventricular mass is proven to have a detrimental effect on long-term&#xD;
      cardiovascular event-free survival, and ventricular hypertrophy is increasingly recognized as&#xD;
      a potent risk factor of cardiovascular morbidity and mortality, and all-cause mortality.&#xD;
      Ventricular performance is altered in hypertension with inappropriate mass, but this&#xD;
      alteration can be subtle enough to escape detection using current echocardiography measures.&#xD;
      Hence, patients with hypertension, who have inappropriate left ventricular mass, need to be&#xD;
      specifically identified by analysis of the predicted and observed ventricular mass, and the&#xD;
      therapeutic goal must include management of elevated blood pressure as well as reversal of&#xD;
      the excessive ventricular mass.&#xD;
&#xD;
      In this double-blind prospective study, patients with hypertension and inappropriate&#xD;
      ventricular mass will be randomized to therapy with nebivolol or metoprolol to find out&#xD;
      whether nebivolol could reverse inappropriate left ventricular mass, thus providing a benefit&#xD;
      beyond what is achieved by mere blood pressure reduction alone. If confirmed, this will&#xD;
      represent a significant ancillary ability of nebivolol and be a key step towards therapy of&#xD;
      inappropriate ventricular mass, which is a so far unmanaged cardiovascular risk and a poor&#xD;
      event-free prognostic factor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in identifying subjects satisfying the inclusion criteria.&#xD;
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Inappropriate Left Ventricular Mass (LVM)</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>LVM will be measured by echocardiography exam. LVM is inappropriate when observed LVM (oLVM) exceeds predicted LVM (pLVM) by more than 28%, that is, 100×(oLVM/pLVM) &gt;128%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Nebivolol 2.5 mg once daily</description>
    <arm_group_label>Nebivolol</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol succinate</intervention_name>
    <description>Metoprolol succinate 50 mg once daily</description>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <other_name>Toprol XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All candidates must have previously untreated hypertension. The candidates will be picked&#xD;
        from patients with stage-1 hypertension (systolic BP 140-159 mm Hg or diastolic BP 90-99 mm&#xD;
        Hg) and those with stage-2 hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥100),&#xD;
        based on the seventh report of the Joint National Committee on Prevention, Detection,&#xD;
        Evaluation, and Treatment of High Blood Pressure guidelines (JNC-7).&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of inappropriate LVM.&#xD;
&#xD;
          -  Presence of phenotype of inappropriate LVM.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The criteria will assure that only patients with hypertension are enrolled, that is,&#xD;
        excluded will be subjects with systolic BP &lt; 140 or diastolic BP &lt; 90 (ie, prehypertension&#xD;
        or normal BP), but without complications or any indication (or suspicion) of end-organ&#xD;
        damage based on a physical exam, clinical history, or laboratory tests.&#xD;
&#xD;
        Specific exclusion criteria are:&#xD;
&#xD;
          -  Reactive airways disease including asthma.&#xD;
&#xD;
          -  Diabetes mellitus or hypoglycemia; thyrotoxicosis.&#xD;
&#xD;
          -  LV dysfunction (ejection fraction &lt; 50%) or heart failure.&#xD;
&#xD;
          -  Present or previously documented coronary heart disease or angina.&#xD;
&#xD;
          -  Acute myocardial infarction, or history of myocardial infarction.&#xD;
&#xD;
          -  Severe bradycardia, heart block greater than first degree or sick sinus syndrome&#xD;
             (unless a permanent pacemaker is in place).&#xD;
&#xD;
          -  Hepatic insufficiency or history of cirrhosis.&#xD;
&#xD;
          -  Chronic renal failure or renovascular dysfunction.&#xD;
&#xD;
          -  Cerebrovascular dysfunction.&#xD;
&#xD;
          -  Peripheral vascular disease.&#xD;
&#xD;
          -  Pregnant or nursing women; women of childbearing age will be required to take a&#xD;
             pregnancy test at the time of enrollment and use an acceptable method of birth&#xD;
             control.&#xD;
&#xD;
          -  Poor echo image quality.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marek Belohlavek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <results_first_submitted>April 4, 2014</results_first_submitted>
  <results_first_submitted_qc>April 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2014</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Marek Belohlavek</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hypertension, Left Ventricular Mass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol</title>
          <description>Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.&#xD;
Nebivolol: Nebivolol 2.5 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Metoprolol Succinate</title>
          <description>Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.&#xD;
Metoprolol succinate: Metoprolol succinate 50 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was terminated early due to the difficulty in identifying subjects satisfying the inclusion criteria. Only 1 subject was enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol</title>
          <description>Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.&#xD;
Nebivolol: Nebivolol 2.5 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Metoprolol Succinate</title>
          <description>Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.&#xD;
Metoprolol succinate: Metoprolol succinate 50 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Inappropriate Left Ventricular Mass (LVM)</title>
        <description>LVM will be measured by echocardiography exam. LVM is inappropriate when observed LVM (oLVM) exceeds predicted LVM (pLVM) by more than 28%, that is, 100×(oLVM/pLVM) &gt;128%.</description>
        <time_frame>baseline, 6 months</time_frame>
        <population>Data were not collected for the single participant, so no analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.&#xD;
Nebivolol: Nebivolol 2.5 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol Succinate</title>
            <description>Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.&#xD;
Metoprolol succinate: Metoprolol succinate 50 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inappropriate Left Ventricular Mass (LVM)</title>
          <description>LVM will be measured by echocardiography exam. LVM is inappropriate when observed LVM (oLVM) exceeds predicted LVM (pLVM) by more than 28%, that is, 100×(oLVM/pLVM) &gt;128%.</description>
          <population>Data were not collected for the single participant, so no analysis was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol</title>
          <description>Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.&#xD;
Nebivolol: Nebivolol 2.5 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Metoprolol Succinate</title>
          <description>Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.&#xD;
Metoprolol succinate: Metoprolol succinate 50 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early due to the difficulty in identifying subjects satisfying the inclusion criteria. Only 1 subject was enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Marek Belohlavek, M.D., Ph.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>408-301-6694</phone>
      <email>belohlavek.marek@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

